Avaliação da funcionalidade da criança com paralisia cerebral espástica
DOI:
https://doi.org/10.11606/issn.2317-0190.v17i2a103312Palavras-chave:
Criança, Paralisia Cerebral, Espasticidade Muscular, EscalasResumo
A paralisia cerebral é resultante de uma lesão não progressiva sobre o sistema nervoso central em desenvolvimento e que pode levar a disfunções motoras, distúrbios no movimento, deficiências mentais e alterações funcionais. A espasticidade é a anormalidade motora e postural mais comumente vista na paralisia cerebral. Considerando as múltiplas repercussões da espasticidade sobre a funcionalidade do indivíduo com paralisia cerebral, torna-se claro que uma avaliação do quadro clínico deve ser precisa e direcionar-se aos aspectos específicos que exigem intervenção. Este texto tem como objetivo servir de guia aos médicos ou terapeutas na escolha de instrumentos de medição quantitativa e qualitativa.
Downloads
Referências
Elovic E. Principles of pharmaceutical management of spastic hypertonia. Phys Med Rehabil Clin N Am. 2001;12(4):793-816.
Kerr Graham H, Selber P. Musculoskeletal aspects of cerebral palsy. J Bone Joint Surg Br. 2003;85(2):157-66.
Wissel J, Müller J, Dressnandt J, Heinen F, Naumann M, Topka H, et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage. 2000;20(1):44-9.
Jozefczyk PB. The management of focal spasticity. Clin Neuropharmacol. 2002;25(3):158-73.
Tilton AH. Approach to the rehabilitation of spasticity and neuromuscular disorders in children. Neurol Clin. 2003;21(4):853-81.
Mooney JF 3rd, Koman LA, Smith BP. Pharmacologic management of spasticity in cerebral palsy. J Pediatr Orthop. 2003;23(5):679-86.
Jacobs JM. Management options for the child with spastic cerebral palsy. Orthop Nurs. 2001;20(3):53-9.
Ong HT, Chong HN, Yap SSP. Comprehensive management of spasticity in cerebral palsy: role of physical therapy and other adjunctive treatments. Singapore Paediatr J. 2001;43(4):133-6.
Yaggie JA & Armstrong WJ. Spastic diplegic cerebral palsy: a brief introduction to its characteristics, assessment and treatment options. Clin. kinesiol. 2001;55(4):75-80.
Kopec K. Cerebral palsy: pharmacologic treatment of spasticity. US Pharm. 2008;33(1):22-26.
Téllez de Meneses M, Barbero P, Alvarez-Garijo JA, Mulas F. Intrathecal baclofen and Botulinum toxin in infantile cerebral palsy. Rev Neurol. 2005;40 Suppl 1:S69-73.
Patel DR, Soyode O. Pharmacologic interventions for reducing spasticity in cerebral palsy. Indian J Pediatr. 2005;72(10):869-72.
Gaebler-Spira D, Revivo G. The use of botulinum toxin in pediatric disorders. Phys Med Rehabil Clin North Am. 2003;14(4):703-25.
Pascual-Pascual SI, Herrera-Galante A, Póo P, García-Aymerich V, Aguilar-Barberà M, Bori-Fortuny I, et al. Guidelines for the treatment of child spasticity using botulinum toxin. Rev Neurol. 2007;44(5):303-9.
Graham HK, Aoki KR, Autti-Rämö I, Boyd RN, Delgado MR, Gaebler-Spira DJ, et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture. 2000;11(1):67-79.
Tilton A. Management of spasticity in children with cerebral palsy. Semin Pediatr Neurol. 2004;11(1):58-65.
Gracies JM, Elovic E, McGuire J, Simpson D. Traditional pharmacologic treatments of spasticity. Part I: local treatments. In: Mayer NH, Simpson DM, eds. Spasticity: etiology, evaluation, management and the role of botulinum toxin. New York: WE MOVE; 2002. p.44-64.
Brunstrom JE. Clinical considerations in cerebral palsy and spasticity. J Child Neurol. 2001;16(1):10-5.
Heinen F, Molenaers G, Fairhurst C, Carr LJ, Desloovere K, Chaleat Valayer E, et al. European consensus table 2006 on botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2006;10(5-6):215-25.
Beckung E, Hagberg G. Neuroimpairments, activity limitations, and participation restrictions in children with cerebral palsy. Dev Med Child Neurol. 2002;44(5):309-16.
Rosenbaum P, Stewart D. The World Health Organization International Classification of Functioning, Disability, and Health: a model to guide clinical thinking, practice and research in the field of cerebral palsy. Semin Pediatr Neurol. 2004;11(1):5-10.
Greene WB, Heckman JD. The clinical measurement of joint motion. Rosemonth: American Academy of Orthopaedic Surgeons; 1994.
Allington NJ, Leroy N, Doneux C. Ankle joint range of motion measurements in spastic cerebral palsy children: intraobserver and interobserver reliability and reproducibility of goniometry and visual estimation. J Pediatr Orthop B. 2002;11(3):236-9.
McDowell BC, Hewitt V, Nurse A, Weston T, Baker R. The variability of goniometric measurements in ambulatory children with spastic cerebral palsy. Gait Posture. 2000;12(2):114-21.
Fosang AL, Galea MP, McCoy AT, Reddihough DS, Story I. Measures of muscle and joint performance in the lower limb of children with cerebral palsy. Dev Med Child Neurol. 2003;45(10):664-70.
Damiano DL, Quinlivan JM, Owen BF, Payne P, Nelson KC, Abel MF. What does the Ashworth scale really measure and are instrumented measures more valid and precise? Dev Med Child Neurol. 2002;44(2):112-8.
Tilton AH. Therapeutic interventions for tone abnormalities in cerebral palsy. Neurotherapeutics. 2006;3(2):217-24.
Boyd RN, Graham HK. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol. 1999;6(Suppl 4):S23-S35.
Morris S. Ashworth and Tardieu Scales: their clinical relevance for measuring spasticity in adult and paediatric neurological populations. Phys Ther Rev. 2002;7(1);53-62.
Calderón-González R, Calderón-Sepúlveda RF. Treatment of spasticity in cerebral palsy with botulinum toxin. Rev Neurol. 2002;34(1):52-9.
Haugh AB, Pandyan AD, Johnson GR. A systematic review of the Tardieu scale for the measurement of spasticity. Disabil Rehabil. 2006;28(15):899-907.
Desloovere K, Molenaers G, Jonkers I, De Cat J, De Borre L, Nijs J, et al. A randomized study of combined botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures. Eur J Neurol. 2001;8 Suppl 5:75-87.
Zürcher AW, Molenaers G, Desloovere K, Fabry G. Kinematic and kinetic evaluation of the ankle after intramuscular injection of botulinum toxin A in children with cerebral palsy. Acta Orthop Belg. 2001;67(5):475-80.
Molenaers G, Desloovere K, Fabry G, De Cock P. The effects of quantitative gait assessment and botulinum toxin A on musculoskeletal surgery in children with cerebral palsy. J Bone Joint Surg Am. 2006;88(1):161-70.
Maloney FP, Mirrett P, Brooks C, Johannes K. Use of the Goal Attainment Scale in the treatment and ongoing evaluation of neurologically handicapped children. Am J Occup Ther. 1978;32(8):505-10.
Maloney FP. Goal attainment scaling. Phys Ther. 1993;73(2):123.
Palisano RJ. Validity of goal attainment scaling in infants with motor delays. Phys Ther. 1993;73(10):651-8.
Cusick A, McIntyre S, Novak I, Lannin N, Lowe K. A comparison of goal attainment scaling and the Canadian Occupational Performance Measure for paediatric rehabilitation research. Pediatr Rehabil. 2006;9(2):149-57.
Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997;39(4):214-23.
Wood E, Rosenbaum P. The gross motor function classification system for cerebral palsy: a study of rehabilitation and stability over time. Dev Child Neurol. 2000;42(5):292-6.
Palisano RJ, Hanna SE, Rosenbaum PL, Russell DJ, Walter SD, Wood EP, et al. Validation of a model of gross motor function for children with cerebral palsy. Phys Ther. 2000;80(10):974-85.
Eliasson AC, Krumlinde- Sundholm L, Shaw K, Wang C. Effects of constraint- induced movement therapy in young children with hemiplegic cerebral palsy: an adapted model. Dev Med Child Neurol. 2005;47(4):266-75.
WeeFIM System SM. Clinical Guide [computer program]. Version 5.01. Buffalo (NY): University at Buffalo; 2000.
Feldman AB, Haley SM, Coryell J. Concurrent and construct validity of the pediatric evaluation of disability inventory. Phys Ther. 1990;70(10):602-10.
DeMatteo C, Law M, Russell D, Pollock N, Rosenbaum P, Walter S. QUEST: Quality of Upper Extremity Skills Test. Hamilton: McMaster University, Neurodevelopmental Clinical Research Unit; 1992.
Mackey AH, Lobb GL, Walt SE, Stott NS. Reliability and validity of the Observational Gait Scale in children with spastic diplegia. Dev Med Child Neurol. 2003;45(1):4-11.
Maathuis KG, van der Schans CP, van Iperen A, Rietman HS, Geertzen JH. Gait in children with cerebral palsy: observer reliability of Physician Rating Scale and Edinburgh Visual Gait Analysis Interval Testing scale. J Pediatr Orthop. 2005;25(3):268-72.
Read HS, Hazlewood ME, Hillman SJ, Prescott RJ, Robb JE. Edinburgh visual gait score for use in cerebral palsy. J Pediatr Orthop. 2003;23(3):296-301.
Rose J, Gamble JG, Lee J, Lee R, Haskell WL. The energy expenditure index: a method to quantitate and compare walking energy expenditure for children and adolescents. J Pediatr Orthop. 1991;11(5):571-8.
Ijzerman MJ, Nene AV. Feasibility of the physiological cost index as an outcome measure for the assessment of energy expenditure during walking. Arch Phys Med Rehabil. 2002;83(12):1777-82.
Keefer DJ, Tseh W, Caputto JL, Apperson K, McGreal S, Morgan DW. Comparison of direct and indirect measures of walking energy expenditure in children hemiplegic cerebral palsy. Dev Med Child Neurol. 2004;46(5):320-4.
Meythaler JM, Guin-Renfroe S, Grabb P, Hadley MN. Long- term continuously insufed intrathecal baclofeno for spastic-dystonic hypertonia in traumatic brain injury: 1-year experience. Arch Phys Med Rehab. 1999;80(1):13-9.
Camargo CH, Teive HA, Zonta M, Silva GC, Oliveira MR, Roriz MM, et al. Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy. Arq Neuropsiquiatr. 2009;67(1):62-8.
Chutorian AM. Botulinum toxin therapy in children. In Pediatr. 2001;16(3):158-63.
Kiresuk TJ, Smith A, Cardillo JE. Goal attainment scaling: application theory and measurement. Hilsdale: Lawrence Eribaum; 1994.
O'Brien C. Management of spasticity associated with stroke. In: O'Brien C, Yablon S, editors. Management of spasticity with botulinum toxin. Littleton: Postgraduate Institute for Medicine; 1995. p.7-10.
Keith RA, Granger CV, Hamilton BB, Sherwin FS. The functional independence measure: a new tool for rehabilitation. Adv Clin Rehabil. 1987;1:6-18.
Guide for the Uniform Data Set for Medical Rehabilitation (Adult FIM) [computer program]. Version 4.0. Buffalo (NY): University at Buffalo, Fundation Activities; 1993.
Hamilton BB, Laughlin JA, Fiedler RC, Granger CV.Interrater reliability of the 7-level functional independence measure (FIM). Scand J Rehabil Med. 1994;26(3):115-9.
Riberto M, Miyazaki MH, Jorge Filho D, Sakamoto H, Battistella LR. Reprodutibilidade da versão brasileira da Medida de Independência Funcional. Acta Fisiatr. 2001;8(1):45-52. Doi: https://doi.org/10.5935/0104-7795.20010002
Riberto M, Myiazaki MH, Jucá SSH, Sakamoto H, Pinto PPN, Battistella LR. Validação da versão brasileira da Medida de Independência Funcional. Acta Fisiatr. 2004;11(2):72-6. Doi: https://doi.org/10.5935/0104-7795.20040003
Riberto M, Pinto PPN, Sakamoto H, Battistella LR. Independência Funcional de pacientes com lesão medular. 2005;12(2):61-6. Doi: https://doi.org/10.5935/0104-7795.20050004
Mahoney FI, Barthel DW. Functional evaluation: the barthel index. Md State Med J. 1965;14:61-5.
Novak S, Johnson J, Greenwood R. Barthel revisited: making guidelines work. Clin Rehabil. 1996;10:128-34.
Giné-Garriga M, Guerra M, Marí-Dell'Olmo M, Martin C, Unnithan VB. Sensitivity of a modified version of the 'timed get up and go' test to predict fall risk in the elderly: a pilot study. Arch Gerontol Geriatr. 2009;49(1):e60-6.
Pina LV, Loureiro APC. O GMFM e sua aplicação na avaliação motora de crianças com paralisia cerebral. Fisioter Mov. 2006;19(2):91-100.
Gibson N, Graham HK, Love S. Botulinum toxin A in the management of focal muscle overactivity in children with cerebral palsy. Disabil Rehabil. 2007;29(23):1813-22.
Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. GMFCS - E & R Gross Motor Function Classification System Expanded and Revised 2007 [text on the internet]. Hamilton: CanChild Centre for Childhood Disability Research, McMaster University [cited 2010 April 15]. Available from: http://motorgrowth.canchild.ca/en/gmfcs/resources/gmfcs-er.pdf
Chagas PSC, Defilipo EC, Lemos RA, Mancini MC, Frônio JS, Carvalho RM. Classificação da função motora e do desempenho funcional de crianças com paralisia cerebral. Rev Bras Fisioter. 2008;12(5):409-416.
Mancini MC. Inventário de avaliação pediátrica de incapacidade (PEDI): manual da versão brasileira adaptada. Belo Horizonte: UFMG; 2005.
Eliasson AC, Krumlinde-Sundholm L, Rösblad B, Beckung E, Arner M, Ohrvall AM, et al. The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Dev Med Child Neurol. 2006;48(7):549-54.
Carnahan KD, Arner M, Hägglund G. Association between gross motor function (GMFCS) and manual ability (MACS) in children with cerebral palsy. A population-based study of 359 children. BMC Musculoskelet Disord. 2007;8:50.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2010 Acta Fisiátrica
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
